45 related articles for article (PubMed ID: 38158099)
1. Danggui Buxue Tang improves therapeutic efficacy of doxorubicin in triple negative breast cancer via ferroptosis.
Gong G; Ganesan K; Liu Y; Huang Y; Luo Y; Wang X; Zhang Z; Zheng Y
J Ethnopharmacol; 2024 Apr; 323():117655. PubMed ID: 38158099
[TBL] [Abstract][Full Text] [Related]
2. Ononin triggers ferroptosis-mediated disruption in the triple negative breast cancer both in vitro and in vivo.
Gong G; Wan Y; Liu Y; Zhang Z; Zheng Y
Int Immunopharmacol; 2024 May; 132():111959. PubMed ID: 38554442
[TBL] [Abstract][Full Text] [Related]
3. [Stellera chamaejasme against multidrug resistance of triple-negative breast cancer MDA-MB-231 cell through Nrf2].
Zeng R; Wang XX; Cui XH; Yang Q; Zhu XX; Wang YJ
Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(8):2222-2229. PubMed ID: 38812237
[TBL] [Abstract][Full Text] [Related]
4. Peiminine triggers ferroptosis to inhibit breast cancer growth through triggering Nrf2 signaling.
Yi N; Wang L; Jiang Z; Xu G; Li L; Zhang Y; Tan Y
Tissue Cell; 2024 Apr; 87():102323. PubMed ID: 38412577
[TBL] [Abstract][Full Text] [Related]
5. Novel Withanolides from
Huang L; Wei Y; Ni M; Hu H; Xi L; Wang C; Zhu Z; Yang B; Zhao H
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675657
[TBL] [Abstract][Full Text] [Related]
6. SOCS1 acts as a ferroptosis driver to inhibit the progression and chemotherapy resistance of triple-negative breast cancer.
Wang Y; Pang X; Liu Y; Mu G; Wang Q
Carcinogenesis; 2023 Dec; 44(8-9):708-715. PubMed ID: 37665951
[TBL] [Abstract][Full Text] [Related]
7. Bioactive compound schaftoside from Clinacanthus nutans attenuates acute liver injury by inhibiting ferroptosis through activation the Nrf2/GPX4 pathway.
Yu Y; Liang J; Yuan Z; Wang A; Liu X; Chen Y; Zhang M; Gao Y; Zhang H; Liu Y
J Ethnopharmacol; 2024 Jun; 328():118135. PubMed ID: 38556139
[TBL] [Abstract][Full Text] [Related]
8. Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.
Stern S; Liang D; Li L; Kurian R; Lynch C; Sakamuru S; Heyward S; Zhang J; Kareem KA; Chun YW; Huang R; Xia M; Hong CC; Xue F; Wang H
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35579950
[TBL] [Abstract][Full Text] [Related]
9. Ling-Gui-Zhu-Gan decoction protects against doxorubicin-induced myocardial injury by downregulating ferroptosis.
Yang YL; Zhao CZ; Zhao CC; Wen ZY; Ma YY; Zhao XN; Wang L; Huang JL; Zhou P
J Pharm Pharmacol; 2024 Apr; 76(4):405-415. PubMed ID: 38241142
[TBL] [Abstract][Full Text] [Related]
10. Rhein potentiates doxorubicin in treating triple negative breast cancer by inhibiting cancer-associated fibroblasts.
Xu S; Zheng S; Ma N; Zhang H; Shi J; Huang J; Luo N; Wang M; Xiong Y
Biochem Pharmacol; 2024 May; 223():116139. PubMed ID: 38499109
[TBL] [Abstract][Full Text] [Related]
11. Nano-inducer of ferroptosis for targeted chemotherapy of human triple negative breast carcinoma.
Shetake NG; Das SK; Kumar A; Pandey BN
Biomater Adv; 2024 Apr; 161():213868. PubMed ID: 38677038
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Nrf2 reverses ferroptosis induced by Arenobufagin in gastric cancer.
Long J; Wang W; Chu J; Li Y; Wang M; Su J; Yang Y; Wang G; Li Q; Cheng H
Toxicol Appl Pharmacol; 2024 Mar; 484():116842. PubMed ID: 38307257
[TBL] [Abstract][Full Text] [Related]
13. G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis.
Sun G; Wang J; Liu F; Zhao C; Cui S; Wang Z; Liu Z; Zhang Q; Xiang C; Zhang Y; Galons H; Yu P; Teng Y
Biochem Pharmacol; 2024 Apr; 222():116077. PubMed ID: 38395264
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.
Patel N; Kommineni N; Surapaneni SK; Kalvala A; Yaun X; Gebeyehu A; Arthur P; Duke LC; York SB; Bagde A; Meckes DG; Singh M
Int J Pharm; 2021 Sep; 607():120943. PubMed ID: 34324983
[TBL] [Abstract][Full Text] [Related]
15. A chemo/chemodynamic nanoparticle based on hyaluronic acid induces ferroptosis and apoptosis for triple-negative breast cancer therapy.
Wang N; Zhang Q; Wang Z; Liu Y; Yang S; Zhao X; Peng J
Carbohydr Polym; 2024 Apr; 329():121795. PubMed ID: 38286559
[TBL] [Abstract][Full Text] [Related]
16. L-lysine Increases the Anticancer Effect of Doxorubicin in Breast Cancer by Inducing ROS-Dependent Autophagy.
Jahani M; Yarani R; Rezazadeh D; Tahmasebi H; Hoseinkhani Z; Kiani S; Mansouri K
Curr Cancer Drug Targets; 2024 Apr; ():. PubMed ID: 38584530
[TBL] [Abstract][Full Text] [Related]
17. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC.
Stravokefalou V; Stellas D; Karaliota S; Nagy BA; Valentin A; Bergamaschi C; Dimas K; Pavlakis GN
Front Immunol; 2022; 13():1014802. PubMed ID: 36713398
[TBL] [Abstract][Full Text] [Related]
18. PTGER3 knockdown inhibits the vulnerability of triple-negative breast cancer to ferroptosis.
Wang S; Zhang Y; Zhang D; Meng J; Che N; Zhao X; Liu T
Cancer Sci; 2024 Apr; ():. PubMed ID: 38566528
[TBL] [Abstract][Full Text] [Related]
19. An ATPase-Mimicking MXene nanozyme pharmacologically breaks the ironclad defense system for ferroptosis cancer therapy.
Wang H; Liu X; Yan X; Du Y; Pu F; Ren J; Qu X
Biomaterials; 2024 Jun; 307():122523. PubMed ID: 38432004
[TBL] [Abstract][Full Text] [Related]
20. DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis.
Cao S; Long X; Xiao L; Zhang P; Shen M; Chen F; Bao C; Zhong X; Luo T; Ye F
Front Oncol; 2024; 14():1356778. PubMed ID: 38549944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
